Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 18/20 | 1.00 |
| ▸ | MEF2D | Q14814 | 18/20 | 1.00 |
| ▸ | EP300 | Q09472 | 3/20 | 0.69 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21232126 | 0.90 | HDAC4 (1.00) | HDAC4MEF2DEP300HDAC3HDAC1 | |
| SCHEMBL21232516 | 0.87 | HDAC4 (1.00) | HDAC4MEF2DEP300HDAC3HDAC1 | |
| SCHEMBL21232499 | 0.85 | HDAC4 (0.86) | HDAC4MEF2DEP300 | |
| SCHEMBL29355772 | 0.85 | HDAC4 (0.81) | HDAC4MEF2DEP300HDAC3HDAC1 | |
| SCHEMBL21232333 | 0.85 | HDAC4 (0.81) | HDAC4MEF2DEP300HDAC3HDAC1 | |
| SCHEMBL21232142 | 0.85 | HDAC4 (0.81) | HDAC4MEF2DEP300HDAC3HDAC1 | |
| SCHEMBL21232524 | 0.85 | HDAC4 (0.81) | HDAC4MEF2DEP300HDAC3HDAC1 | |
| SCHEMBL21232157 | 0.84 | HDAC4 (1.00) | HDAC4MEF2DEP300HDAC3HDAC1 | |
| SCHEMBL21232188 | 0.82 | HDAC4 (1.00) | HDAC4MEF2DEP300 | |
| SCHEMBL29355918 | 0.82 | HDAC4 (1.00) | HDAC4MEF2DEP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11230524-B2 | Myocyte enhancer factor 2 (MEF2) modulators | STANDARD LLC (US) | 2022-01-25 | — | — | US | disclosed |
| US-20190241504-A1 | Novel Myocyte Enhancer Factor 2 (MEF2) modulators | STANDARD LLC | 2019-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11230524-B2 | Myocyte enhancer factor 2 (MEF2) modulators | MEF2D, MYLK2, TNNT2 | HDAC4 81/4885MEF2D 1/4885EP300 35/4885 |
| US-20190241504-A1 | Novel Myocyte Enhancer Factor 2 (MEF2) modulators | MEF2D, MYLK2, MYOF | HDAC4 97/4885MEF2D 1/4885EP300 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.